Taysha Gene Therapies *

Taysha Gene Therapies is a clinical-stage biotechnology company (Dallas, TX with a laboratory in Morrisville, NC) developing AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead program, TSHA-102, targets Rett syndrome and has completed dosing in the REVEAL pivotal trial. The company operates as a therapeutics developer and publishes no public developer API, documentation portal, or technical integration surface; it was surfaced as a GV portfolio company and added to the API Evangelist network as an enrichment lead.

Taysha Gene Therapies * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Therapy, and Rare Disease.

🌐 Visit website 📡 Source on GitHub
3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyGene TherapyRare DiseaseCentral Nervous SystemClinical StagePharmaceuticals

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.3/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/taysha-gene-therapies: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Taysha Gene Therapies Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: taysha-gene-therapies
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/taysha-gene-therapies.png
name: Taysha Gene Therapies *
description: Taysha Gene Therapies is a clinical-stage biotechnology company (Dallas, TX with a laboratory in Morrisville,
  NC) developing AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead program, TSHA-102,
  targets Rett syndrome and has completed dosing in the REVEAL pivotal trial. The company operates as a therapeutics developer
  and publishes no public developer API, documentation portal, or technical integration surface; it was surfaced as a GV portfolio
  company and added to the API Evangelist network as an enrichment lead.
url: https://raw.githubusercontent.com/api-evangelist/taysha-gene-therapies/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Gene Therapy
- Rare Disease
- Central Nervous System
- Clinical Stage
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/taysha-gene-therapies-domain-security.yml
- type: Website
  url: https://tayshagtx.com
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1